

Lipodystrophy - Pipeline Insight, 2021

<https://marketpublishers.com/r/LA192D41A5AFEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: LA192D41A5AFEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Lipodystrophy – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Lipodystrophy Understanding

Lipodystrophy: Overview

Lipodystrophy refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at birth (congenital). There are five types of lipodystrophy: Congenital generalized lipodystrophy, acquired generalized lipodystrophy, Acquired partial lipodystrophy, High active antiretroviral therapy-induced lipodystrophy, and Localized lipodystrophy. The specific symptoms present, severity, and prognosis can vary greatly depending upon the specific type of lipodystrophy and the presence and extent of associated symptoms. To make the medical diagnosis of lipodystrophy the doctor first examine the abnormal appearance caused by changes in fat loss or gain, and then he or she generally look for the

characteristic clinical symptoms and signs.

'Lipodystrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lipodystrophy pipeline landscape is provided which includes the disease overview and Lipodystrophy treatment guidelines. The assessment part of the report embraces, in depth Lipodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lipodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lipodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Lipodystrophy.

Lipodystrophy Emerging Drugs Chapters

This segment of the Lipodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lipodystrophy Emerging Drugs

Volanesorsen (IONIS-APOCIII-LRx): Ionis Pharmaceuticals

IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. The drug is currently being investigated in Phase III stage of development for the treatment of patients with Hyperlipoproteinaemia; Lipodystrophy. The drug has also been granted the Orphan drug designation by U.S FDA and European Medicines Agency.s

Vupanorsen: Pfizer

Vupanorsen is an investigational antisense therapy, discovered by Ionis Pharmaceuticals and co-developed by Ionis and its subsidiary Akcea Therapeutics. Vupanorsen has been developed using Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform to inhibit the production of angiotensin-like 3 (ANGPTL3) protein, which is an important regulator of triglyceride and cholesterol metabolism in the liver. Pfizer has commenced a Phase 2b study of vupanorsen, in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs).

Further product details are provided in the report

Lipodystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Lipodystrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lipodystrophy

There are approx. 10+ key companies which are developing the therapies for Lipodystrophy. The companies which have their Lipodystrophy drug candidates in the most advanced stage, i.e. Phase III include, ContraFect.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Lipodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Lipodystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipodystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipodystrophy drugs.

Lipodystrophy Report Insights

- Lipodystrophy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Lipodystrophy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Lipodystrophy drugs?

How many Lipodystrophy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lipodystrophy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipodystrophy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Lipodystrophy and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Lipodystrophy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Lipodystrophy – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Lipodystrophy companies' collaborations, Licensing, Acquisition -Deal Value Trends

Lipodystrophy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Volanesorsen: Ionis Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Vupanorsen: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
AMX 342: Amunix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Lipodystrophy Key Companies
Lipodystrophy Key Products
Lipodystrophy- Unmet Needs
Lipodystrophy- Market Drivers and Barriers
Lipodystrophy- Future Perspectives and Conclusion
Lipodystrophy Analyst Views
Lipodystrophy Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Lipodystrophy
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Lipodystrophy
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Lipodystrophy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/LA192D41A5AFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LA192D41A5AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970